This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duda, D. G. Articles by Willett, C. G. Search for Related Content PubMed PubMed Citation Articles by Duda, D. G. Articles by Willett, C. G. Social Bookmarking                            What's this?

Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers

Dan G. Duda, Rakesh K. Jain, Christopher G. Willett

From the Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA; and the Department of Radiation Oncology, Duke University Medical Center, Durham, NC

Address reprint requests to Christopher G. Willett, MD, Box 3085, Duke University Medical Center, Durham, NC 27710; e-mail: christopher.willett{at}duke.edu or Dan G. Duda, DMD, PhD, Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom St, Cox-734, Boston, MA 02114; e-mail: duda{at}steele.mgh.harvard.edu

Although still in very early stages of clinical development, the combination of antiangiogenics with contemporary chemoradiotherapy regimens has emerged as a feasible and promising approach to many cancers. We review the rationale and the current understanding of antiangiogenics and their therapeutic potential in combination with chemoradiotherapy. Finally, we offer a perspective on future research directions aimed at making this complex therapeutic approach successful in the clinic.

Supported by National Cancer Institute Grants No. R21 CA099237 (to C.G.W.) and P01 CA80124 and R01 CA115767 (to R.K.J.), a National Foundation for Cancer Research Grant (to R.K.J.) and an American Association for Cancer Research–Genentech BioOncology Career Development Award (to D.G.D.).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Geng, G. Rachakonda, D. J. Morre, D. M. Morre, P. A. Crooks, V. N. Sonar, J. L. R. Roti, B. E. Rogers, S. Greco, F. Ye, et al. Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature FASEB J, September 1, 2009; 23(9): 2986 - 2995. [Abstract] [Full Text] [PDF]

				A. S. Chi, A. G. Sorensen, R. K. Jain, and T. T. Batchelor Angiogenesis as a Therapeutic Target in Malignant Gliomas Oncologist, June 1, 2009; 14(6): 621 - 636. [Abstract] [Full Text] [PDF]

				J. D. Murphy, A. C. Spalding, Y. R. Somnay, S. Markwart, M. E. Ray, and D. A. Hamstra Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature Clin. Cancer Res., January 15, 2009; 15(2): 589 - 596. [Abstract] [Full Text] [PDF]

				P. Y. Wen, A. D. Norden, and J. Drappatz Antiangiogenic Therapies for Malignant Gliomas ASCO Educational Book, January 1, 2009; 2009(1): 113 - 117. [Abstract] [Full Text] [PDF]

				J. H.E. Baker, J. Lam, A. H. Kyle, J. Sy, T. Oliver, S. J. Co, W. H. Dragowska, E. Ramsay, M. Anantha, T. J. Ruth, et al. Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin Clin. Cancer Res., November 15, 2008; 14(22): 7260 - 7271. [Abstract] [Full Text] [PDF]

				A. Idbaih, F. Ducray, M. Sierra Del Rio, K. Hoang-Xuan, and J.-Y. Delattre Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors Oncologist, September 1, 2008; 13(9): 978 - 992. [Abstract] [Full Text] [PDF]

				P. Y. Wen and S. Kesari Malignant Gliomas in Adults N. Engl. J. Med., July 31, 2008; 359(5): 492 - 507. [Full Text] [PDF]

				S. P. Dineen, K. D. Lynn, S. E. Holloway, A. F. Miller, J. P. Sullivan, D. S. Shames, A. W. Beck, C. C. Barnett, J. B. Fleming, and R. A. Brekken Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice Cancer Res., June 1, 2008; 68(11): 4340 - 4346. [Abstract] [Full Text] [PDF]

				N. A.J.B. Peters, D. J. Richel, J. J.C. Verhoeff, and L. J.A. Stalpers Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib J. Clin. Oncol., May 10, 2008; 26(14): 2405 - 2406. [Full Text] [PDF]